Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.55% during intraday trading on Wednesday, driven by a cluster of positive company-specific developments.

The rally follows the company's report of a 24.4% year-over-year increase in revenue, alongside a board-approved share buyback authorization of up to 10% of its issued capital. These financial improvements signal stronger operational performance and a commitment to returning value to shareholders.

Furthermore, a significant regulatory milestone provided a major catalyst. The company's drug candidate GFH375 received a second breakthrough therapy designation, marking it as the first domestically developed KRAS G12D inhibitor monotherapy to be included in a breakthrough therapy list for pancreatic cancer, bolstering investor confidence in its pipeline prospects.